Nexalin Technology Inc (NXL) Stock Price, Quote & News

Company Profile

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injur...

Industry: Medical Devices

Sector: Healthcare

Phone: 832 260 0222

Website: www.nexalin.com

Address:

1776 Yorktown, Suite 550, Houston, United States

Dante_s_Inferno Jan. 26 at 3:16 PM

$NXL pathetic

1 · Reply

isaacwilliams33 Jan. 22 at 6:38 PM

$IPST $NXL about in zone

0 · Reply

NVDAMillionaire Jan. 21 at 3:11 PM

$NXL Outstanding article that hits the mark on NXL's current state. So if you want to refresh your NXL insights or learn about NXL from scratch, this is a must read. https://everyticker.com/quote/NXL/analysis/fda-roulette-nexalin-s-15m-bet-on-a-15-milliamp-brain-wave-nasdaq-nxl

0 · Reply

BillionerOfKing Jan. 20 at 4:36 AM

$NXL Current Stock Price: $0.69

0 · Reply

DARKP00L Jan. 14 at 2:13 PM

$NXL 09:04 on Jan. 14 2026 Nexalin Technology Announces Publication Of New Peer-Reviewed Clinical Study In Molecular Psychiatry Demonstrating DIFS Technology Improves Attention And Normalizes Brain Activity In Patients With ADHD #tradeideas

0 · Reply

MrTicker Jan. 14 at 2:01 PM

$NXL Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHDFour weeks of non-invasive DIFS™ neurostimulation delivers meaningful attention gains alongside objective brain imaging changes GLOBENEWSWIRE 8:00 AM ET 1/14/2026

0 · Reply

Stock_Catcher Jan. 14 at 2:00 PM

$NXL Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

0 · Reply

CocaKolla Jan. 6 at 8:43 PM

$NXL going slow up

1 · Reply

Splendid888 Jan. 5 at 7:16 PM

$NXL NXL is extremely undervalued here. Should back to 1.50 later this month.

0 · Reply

Painman Jan. 2 at 11:00 PM

$NXL You poor Bastards holding this bag of 💩.. The company is a scam. Founder is a notorious scumbag.. The whole thing is a fraud.you can’t do deep brain stimulation with skin electrodes! This has been nothing but a massive pump and dump since it was founded.Check out Len Osser! Good luck, you poor sons of bitches

2 · Reply

Published Peer-Reviewed Study Demonstrates Nexalin's DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

Dec 3, 2025, 8:00 AM EST - 2 months ago

Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program

Dec 2, 2025, 8:00 AM EST - 2 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4

Nov 18, 2025, 9:00 AM EST - 2 months ago

Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

Nov 13, 2025, 9:15 AM EST - 2 months ago

Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

Nov 5, 2025, 8:30 AM EST - 3 months ago

Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer's Disease and Dementia

Oct 30, 2025, 8:30 AM EDT - 3 months ago

Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel

Oct 21, 2025, 9:00 AM EDT - 3 months ago

Nexalin's DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia Across Three Peer-Reviewed Studies

Oct 13, 2025, 8:30 AM EDT - 3 months ago

Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs

Oct 10, 2025, 8:00 AM EDT - 4 months ago

Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit

Oct 8, 2025, 2:45 PM EDT - 4 months ago

Why Is Micro-Cap Stock Nexalin Technology Rallying On Wednesday?

Oct 8, 2025, 8:30 AM EDT - 4 months ago

Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer's Disease with Gen-2 SYNC Neurostimulation Device

Sep 25, 2025, 8:30 AM EDT - 4 months ago

Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology

Aug 25, 2025, 9:00 AM EDT - 5 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on September 9

Aug 1, 2025, 8:30 AM EDT - 6 months ago

Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic Initiatives

May 28, 2025, 10:00 AM EDT - 8 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3

May 13, 2025, 8:30 AM EDT - 9 months ago

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

May 6, 2025, 2:40 PM EDT - 9 months ago

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

May 5, 2025, 8:20 AM EDT - 9 months ago

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

May 1, 2025, 10:30 AM EDT - 9 months ago

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

Apr 24, 2025, 9:00 AM EDT - 10 months ago

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

Apr 23, 2025, 9:15 AM EDT - 10 months ago

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

Apr 21, 2025, 8:00 AM EDT - 10 months ago

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

Apr 14, 2025, 12:30 PM EDT - 10 months ago

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Apr 2, 2025, 8:30 AM EDT - 10 months ago

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Mar 26, 2025, 8:30 AM EDT - 11 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3

Mar 3, 2025, 8:30 AM EST - 11 months ago

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Feb 28, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval

Feb 26, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

Feb 18, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

Feb 10, 2025, 9:00 AM EST - 1 year ago

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Feb 3, 2025, 8:30 AM EST - 1 year ago

Nexalin's Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Jan 23, 2025, 11:00 AM EST - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Dec 23, 2024, 10:00 AM EST - 1 year ago

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

Nov 26, 2024, 10:00 AM EST - 1 year ago

New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Nov 1, 2024, 2:00 PM EDT - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th

Nov 1, 2024, 10:34 AM EDT - 1 year ago

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

Nov 1, 2024, 9:00 AM EDT - 1 year ago

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

LOBO

Oct 28, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

Oct 25, 2024, 9:00 AM EDT - 1 year ago

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CLDI

Oct 22, 2024, 2:15 PM EDT - 1 year ago

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

Oct 17, 2024, 8:30 AM EDT - 1 year ago

New Study Shows Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer's Patients

Oct 14, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

Sep 5, 2024, 9:00 AM EDT - 1 year ago

Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

Jul 26, 2024, 9:55 AM EDT - 1 year ago

Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

LOBO

Jul 18, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

Jul 1, 2024, 2:45 PM EDT - 1 year ago

Nexalin Technology Announces Closing of $5.2 Million Public Offering

Jun 27, 2024, 9:15 PM EDT - 1 year ago

Nexalin Technology Announces Pricing of $5.2 Million Public Offering

Jun 20, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer's and Dementia

Jun 14, 2024, 9:00 AM EDT - 1 year ago

Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

VNRX

Dante_s_Inferno Jan. 26 at 3:16 PM

$NXL pathetic

1 · Reply

isaacwilliams33 Jan. 22 at 6:38 PM

$IPST $NXL about in zone

0 · Reply

NVDAMillionaire Jan. 21 at 3:11 PM

0 · Reply

BillionerOfKing Jan. 20 at 4:36 AM

$NXL Current Stock Price: $0.69

0 · Reply

DARKP00L Jan. 14 at 2:13 PM

0 · Reply

MrTicker Jan. 14 at 2:01 PM

0 · Reply

Stock_Catcher Jan. 14 at 2:00 PM

$NXL Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

0 · Reply

CocaKolla Jan. 6 at 8:43 PM

$NXL going slow up

1 · Reply

Splendid888 Jan. 5 at 7:16 PM

$NXL NXL is extremely undervalued here. Should back to 1.50 later this month.

0 · Reply

Painman Jan. 2 at 11:00 PM

2 · Reply

Dante_s_Inferno Dec. 30 at 3:44 PM

$NXL new lows every f* day

2 · Reply

wolfcyd3 Dec. 26 at 8:52 PM

$NXL added here

0 · Reply

Dante_s_Inferno Dec. 26 at 8:36 PM

$NXL f* pos RSI 24

0 · Reply

NewYorkBull Dec. 26 at 5:27 PM

$NXL does anyone know what is going on here? just hit 52 week low

1 · Reply

TheInformationR Dec. 25 at 8:38 AM

$NXL Upside depends on translating ambition into measurable cadence, since capital markets reward discipline over expansion for its own sake. Proof points carry more weight than guidance alone.

0 · Reply

Dante_s_Inferno Dec. 15 at 3:02 PM

$NXL shix show again 💪🏻👏🏻

0 · Reply

Stock_Catcher Dec. 3 at 1:29 PM

$NXL Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program

0 · Reply

Dante_s_Inferno Dec. 1 at 3:35 PM

$NXL one step forward and two steps back

0 · Reply

Azlvr Nov. 21 at 7:42 PM

$NXL 😬 https://www.trustpilot.com/review/www.jccapitalconsultants.com

1 · Reply

Stockprofiler Nov. 18 at 5:43 PM

$ILLR #Undervalued (Nasdaq: ILLR) #BKFC is valued at over $400M and as much as $1B 2025-2026 •TRILLER currently seriously undervalued at $140M •News highly anticipated based on most recent PRs https://nasdaq.com/market-activity/stocks/illr/press-releases $META $NXL

0 · Reply

Dante_s_Inferno Nov. 18 at 3:14 PM

$NXL f* scam

0 · Reply

MrTicker Nov. 18 at 2:03 PM

$NXL Nexalin Technology Study On 15 Milliamp Neurostimulation Device Demonstrates Safety, Efficacy In Participant With Gambling Disorder, Alcohol Use Disorder BENZINGA 8:03 AM ET 11/18/2025

0 · Reply

Market Cap	10.63M
Revenue (ttm)	170,000.00
Net Income (ttm)	-7.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,476.47%
Debt to Equity Ratio	0.00

Volume	39,200
Avg Vol	148,600
Day's Range	N/A - N/A
Shares Out	18.65M
Stochastic %K	14%
Beta	3.94
Analysts	Strong Sell
Price Target	$4.00